Skip to content

Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis

Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis:a Multicenter Prospective Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06251687
Enrollment
100
Registered
2024-02-09
Start date
2024-02-01
Completion date
2026-12-31
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Fibrosis, Transbronchial Cryobiopsy

Brief summary

The goal of this clinical study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy(TBLC)in progressive pulmonary fibrosis. The main question it aims to answer are: • Determine the prognosis, health economics, and therapeutic strategy changes of patients with TBLC retrograde malleable pulmonary fibrosis. Participants will be randomly divided into two groups, and received TBLB or TBLC.

Interventions

PROCEDURETransbronchial Cryobiopsy,TBLC

Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases

PROCEDURETransbronchial Lung Biopsy,TBLB

Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease

Sponsors

China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Patients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, Body mass index (BMI)≤35 kg/m2.

Exclusion criteria

Patients with platelet counts below 50,000×109/L or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC

Design outcomes

Primary

MeasureTime frameDescription
the diagnostic performance of transbronchial cryobiopsy(TBLC)1 month after transbronchial cryobiopsythe sensitivity and specificity of transbronchial cryobiopsy(TBLC)in suspected progressive pulmonary fibrosis

Secondary

MeasureTime frameDescription
the safety of transbronchial cryobiopsy(TBLC)7 days and 1 month after transbronchial cryobiopsyThe occurence of short-term procedure-related complications, including Bleeding, pneumothorax, death, etc

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026